Dasatinib-Induced Polymyositis-Like Syndrome: A Report of a Rare Case.

Myositis is an inflammatory muscle disease characterized by chronic inflammation, progressive muscle weakness, and various systemic effects. Dasatinib, a tyrosine kinase inhibitor (TKI), is commonly used as a first-line treatment for chronic myelogenous leukemia (CML). Although it is generally effective, there have been rare cases where dasatinib can induce muscle damage, leading to muscle weakness.

Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice.

Objective: SLE is an autoimmune disease characterised by persistent inflammation and autoantibody production. Genetic predisposition and environmental factors such as a high-fat diet (HFD) may contribute to lupus development. However, the immune cell profile and gender difference in response to HFD in lupus have not been reported.

Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with Infliximab: a case-based review.

Background: SDRIFE is a rare cutaneous eruption characterized by symmetrical intertriginous dermatitis, caused by delayed Type-IV immune reaction, with several reported drug-triggers.

Objective: We present a case of SDRIFE associated with infliximab in a 70-year-old female with rheumatoid arthritis, and review cases of SDRIFE associated with TNF-inhibitors.

Methods: A literature review about SDRIFE cases associated with TNF-inhibitors was performed.